SYNAGIS - SYNAGIS - CT 5014 - English version

Has

Description

Introduction SYNAGIS 50 mg, powder and solvent for solution for injection Pack of 1 (CIP: 352 314-1) SYNAGIS 100 mg, powder and solvent for solution for injection Pack of 1 (CIP: 352 155-0) Posted on Dec 14 2009 Active substance (DCI) palivizumab ATC Code J06BB16 Laboratory / Manufacturer ABBOTT FRANCE SYNAGIS 50 mg, powder and solvent for solution for injection Pack of 1 (CIP: 352 314-1) SYNAGIS 100 mg, powder and solvent for solution for injection Pack of 1 (CIP: 352 155-0) Posted on Dec 14 2009

Sujets

• Médecine

Informations

• Publié par: haute-autorite-sante-traitement-medicamenteux
• Publié le: 19 décembre 2007
• Nombre de lectures: 27
• Licence : En savoir +
  Paternité, pas d'utilisation commerciale, partage des conditions initiales à l'identique
• Langue: English

Extrait

   

      The legally binding text is the original French version  

TRANSPARENCY COMMITTEE   OPINION   19 December 2007       SYNAGIS 50 mg, powder and solvent for solution for injection Pack of 1 (CIP: 352 314-1)   SYNAGIS 100 mg, powder and solvent for solution for injection Pack of 1 (CIP: 352 155-0)     Applicant: ABBOTT France   palivizumab    ATC code: J06BB16   List I   Date of first MA: 13/08/1999 Date of last clinical variation of MA: 25/07/2006   Inclusion on the list of medicines approved for use by hospitals and various public services   Reason for request: Examination of the pediatric cohort study of children treated by Synagis (study requested by the Transparency Committee   opinion of 13 October 2004 and 8in its November 2006).                                 Medical, Economic and Public Health Assessment Division

 

1